Caplyta (Lumateperone) Indications
Caplyta is FDA-approved for treating schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, either as monotherapy or as adjunctive therapy with lithium or valproate. 1
FDA-Approved Indications
Schizophrenia
- Lumateperone 42 mg once daily is approved for the treatment of schizophrenia in adults 1
- In phase 3 trials, lumateperone 42 mg demonstrated statistically significant improvement versus placebo on the Positive and Negative Syndrome Scale (PANSS) total score (least-squares mean difference -4.2; effect size -0.3; P = 0.02) at day 28 2
- The medication showed efficacy for improving psychotic symptoms with a favorable safety profile, including minimal extrapyramidal symptoms and no clinically significant changes in cardiometabolic or endocrine factors 2
Bipolar Depression (Bipolar I or II Disorder)
- Caplyta is approved for depressive episodes associated with bipolar I or bipolar II disorder, both as monotherapy and as adjunctive therapy with lithium or valproate 1
- In phase 3 trials for bipolar depression, lumateperone 42 mg significantly improved Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo (least squares mean difference -4.6 points; effect size -0.56) at day 43 3
- Efficacy was demonstrated in both bipolar I and bipolar II disorder populations 3
- The medication was generally well tolerated with minimal extrapyramidal symptoms, weight changes, or metabolic abnormalities 3
Emerging Clinical Applications (Not FDA-Approved)
Major Depressive Disorder (Adjunctive Therapy)
- Recent phase 3 trials have evaluated lumateperone 42 mg as adjunctive therapy to antidepressants in patients with major depressive disorder who had inadequate response to 1-2 antidepressant trials 4, 5
- Adjunctive lumateperone significantly improved MADRS total scores (least squares mean difference -4.5 to -4.9; effect size -0.56 to -0.61) compared to placebo plus antidepressant at day 43 4, 5
- This indication is currently under investigation and not yet FDA-approved 4, 5
Major Depressive Disorder or Bipolar Depression With Mixed Features
- A 2025 trial demonstrated efficacy in treating major depressive episodes with mixed features, showing significant improvement in MADRS scores (least squares mean difference -5.7; effect size -0.64; P < 0.0001) in combined MDD/bipolar depression populations 6
- This represents an investigational use not currently included in FDA labeling 6
Mechanism of Action Context
- Lumateperone is classified as an atypical antipsychotic that functions as a simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission 7, 8
- It acts as a partial agonist at dopamine D2 receptors while maintaining 5HT2A antagonism, similar to other atypical antipsychotics 9
- This mechanism distinguishes it from typical antipsychotics and contributes to its lower risk of extrapyramidal symptoms 9
Key Safety Considerations
- Black box warnings include increased risk of death in elderly patients with dementia-related psychosis (not an approved indication) and increased risk of suicidal thoughts and actions in children, adolescents, and young adults 1
- The medication may cause drowsiness, requiring caution with activities requiring mental alertness until individual response is known 1
- Patients should be monitored for metabolic parameters (blood sugar, lipids, weight), though lumateperone demonstrates a favorable metabolic profile compared to many other atypical antipsychotics 1, 8
- It is not approved for use in children 1